Background/Aim: Most patients with small cell lung cancer (SCLC) experience relapse within one year after first-line treatment. The aim of this study was to describe activity and safety of second-line with epirubicin at 70 mg/m2 followed by paclitaxel at 135 mg/m2 on day 1 every three weeks for a maximum of six cycles. Patients and Methods: This is a retrospective review of all patients with SCLC evaluated for second-line treatment between 2003 and 2013 at our Institution. Results: Sixty-eight patients received the study regimen of epirubicin with paclitaxel. We observed partial response in 19 (30%), stable disease in 22 (34%) and total early failure rate in 23 (36%) patients. Median progression free and overall survival were 21.8 and 26.5 weeks, respectively. Haematological toxicities were as follows: grade 3-4 leukopenia and neutropenia in 18 (31%) and 30 (22%) of patients, respectively; grade 3 anaemia and grade 4 thrombocytopenia were reported in 2 (3%) and 5 (9%) of patients, respectively. Conclusion: Epirubicin with paclitaxel is an active and tolerable second-line regimen in patients with SCLC.
|Number of pages||7|
|Publication status||Published - Apr 1 2015|
- Small cell carcinoma
ASJC Scopus subject areas
- Cancer Research